10-Q due out in 3 days. Will Axim delay it again by another week? Maybe there is good reason to delay, but what it says to currently disenchanted shareholders speaks volumes, and not in a good way.
I do have to give an "at-a-boy" to one of Axim's staff. Over a year ago, Peter O'Rouke (who is on the board at Axim) formed a SPAC, which just last week (11/7/2022) finally announced its target - Profusa, Inc.
It looks like a smart choice, and I can see a lot of similarity in the business plan between the Axim/Sapphire merger and the NVAC/Profusa merger. Profusa has developed a tiny hydrofiber implant (3mm by .5mm) that is injected under the skin and does not elicit an immune/rejection response. This fiber can be used for months if not years, and when hit with certain wavelengths of light, molecules in this fiber fluoresce. The light that is emitted can be read and accurately reports various characteristics of intercellular fluid - such as glucose concentrations, oxygen levels, biochemical exposure (military uses), presence of flu particles, etc. Profusa already has a CE Mark for this fiber ("Lumee") in the EU and will seek FDA approval here in the United States after the merger is complete.
I could go on and on with how similar things are in the comparison between AXIM/SAPPHIRE and NVAC/PROFUSA (global market, multiple uses for the same "reader", novel product that is superior to current testing methods in a plethora of ways, R&D company at the onset of its revenue phase, etc.) but the most important point: Peter O'Rouke is on the Board at Axim and able to impart his same business brilliance to Axim, the business plan to bring Axim's products and Profusa's products to market are practically identical, tested, and proven, and the management at Axim (as we have seen) are serious professionals and crisis-tested experts with the goal of making their company and their products an unprecedented success.
It is going to take more time, but emerging companies with novel products that are more efficient, economical, and less invasive and inconvenient, with outstanding shares of 250 million or less and the potential for a not-so-far-into-the-future multi-billion dollar market cap are a rare find.
Godspeed to the Axim shareholders who have come this far and are willing to stick it out a bit longer.
My posts are merely my unprofessional opinion and should NEVER be seen as or used as investment advice,
